Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Sequana Medical NV's operating assets for the quarter that ended in Jun. 2025 was €7.26 Mil. Sequana Medical NV's operating liabilities for the quarter that ended in Jun. 2025 was €12.34 Mil. Sequana Medical NV's Total Assets for the quarter that ended in Dec. 2024 was €9.94 Mil. Therefore, Sequana Medical NV's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2025 was -0.51.
Sequana Medical NV Scaled Net Operating Assets Related Terms
Sequana Medical NV Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sequana Medical NV Scaled Net Operating Assets Chart
STU:2SE vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Sequana Medical NV's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sequana Medical NV Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Sequana Medical NV's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.51 mean?
Sequana Medical NV (STU:2SE) has a Scaled Net Operating Assets of -0.51 as of Jun. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sequana Medical NV and its competitors.
Is Sequana Medical NV's Scaled Net Operating Assets too high?
Sequana Medical NV's current Scaled Net Operating Assets is -0.51. Overall, Sequana Medical NV has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Scaled Net Operating Assets compare to ABT and SYK?
Sequana Medical NV's Scaled Net Operating Assets of -0.51 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sequana Medical NV and its competitors. Sequana Medical NV's current Scaled Net Operating Assets is -0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Based on GuruFocus' analysis, Sequana Medical NV (STU:2SE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 168.9% above its estimated fair value. The current Scaled Net Operating Assets is -0.51. Sequana Medical NV's overall GF Score™ is 34/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sequana Medical NV (STU:2SE), the current Scaled Net Operating Assets is -0.51 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (STU:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 168.9% above its estimated GF Value™ of €0.19.
GuruFocus considers Sequana Medical NV to be Significantly Overvalued.
Key valuation signals for STU:2SE:
Scaled Net Operating Assets: -0.51
GF Value™: €0.19 vs. price of €0.51 (168.9% above fair value)
No single metric tells the full story. See the STU:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
34GF Score
Get the complete analysis for STU:2SE
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2SE has been successfully added to your 
